Published in Drug Week, September 29th, 2006
According to the agreement, Endo will stop selling infringing versions of OxyContin by the end of 2006. In exchange, Purdue Pharma will not pursue damages against Endo for Endo's past infringement of its OxyContin patents.
On February 1, 2006, the United States Court of Appeals for the Federal Circuit ruled that Endo's extended-release oxycodone products...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-09-29)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.